These three treatments are often grouped together as “psychedelic therapy,” but they are not interchangeable. Psilocybin, MDMA, and ketamine differ in mechanism, legal status, session structure, clinical evidence, and which conditions they best fit.
Published
Chief Bear · ~11 min read
Psilocybin is strongest as a deep, long-session treatment model for depression, end-of-life distress, and addiction research. MDMA has the strongest trauma/PTSD-specific evidence but is not FDA-approved as of this update. Ketamine is legally available now for depression care and can act quickly, but often requires maintenance.
| Factor | Psilocybin | MDMA | Ketamine |
|---|---|---|---|
| Best-known clinical fit | Depression, end-of-life distress, addiction research | PTSD and trauma-focused psychotherapy | Treatment-resistant depression and rapid symptom relief |
| Core experience | Classic psychedelic; altered perception and meaning-making | Empathogen; fear reduction and emotional openness | Dissociative; altered body/self perception and rapid mood shift |
| Typical session length | 4-8 hours | 6-8 hours in assisted-therapy protocols | 40-60 minutes for infusions; longer monitoring window |
| U.S. legal access | State-supervised access in Oregon and Colorado; federally Schedule I | Research/regulatory pathway; not FDA-approved as of this update | Ketamine is legal by prescription; esketamine is FDA-approved |
| Main screening issues | Psychosis/bipolar risk, lithium, MAOIs, cardiac risk | Cardiac risk, blood pressure, trauma stability, misuse risk | Blood pressure, dissociation, bladder risk, misuse potential |
Psilocybin is converted to psilocin, which primarily activates serotonin 5-HT2A receptors. The acute experience can loosen rigid thinking, amplify emotion, and create a window for integration afterward. That is why preparation and post-session therapy matter so much.
MDMA is not a classic psychedelic in the same way. It increases serotonin, norepinephrine, dopamine, oxytocin-related social bonding, and fear-extinction conditions. In therapy, the key idea is that traumatic material may become easier to approach without the same level of avoidance or defensive shutdown.
Ketamine acts mainly through glutamate/NMDA pathways and produces dissociation. It can work quickly for depressive symptoms, including acute suicidal ideation signals in some clinical contexts, but the benefit often requires a series of sessions or maintenance care.
The cleanest way to compare these treatments is by condition, not by cultural popularity. Psilocybin has strong depression and existential-distress evidence, plus emerging addiction data. MDMA has the most developed PTSD-specific assisted-therapy evidence, but regulatory status is still unresolved. Ketamine has the strongest legal clinical availability for depression because it is already used in medical settings.
| Condition / goal | Most relevant option | Why |
|---|---|---|
| Major depression / TRD | Psilocybin or ketamine | Psilocybin may be more durable; ketamine is legal and faster acting. |
| PTSD / trauma processing | MDMA | MDMA has the strongest trauma-specific trial program among the three. |
| End-of-life distress | Psilocybin | Strong historic evidence from cancer-related anxiety and existential distress trials. |
| Need rapid legal treatment access | Ketamine | Available through licensed clinics; esketamine has FDA approval for specific depression indications. |
Ketamine is the easiest of the three to access legally in the United States because it is a prescription medication and esketamine has FDA approval for treatment-resistant depression-related indications. Psilocybin access is legal only in limited state-supervised settings such as Oregon and Colorado, while still federally Schedule I.
MDMA-assisted therapy is different again: strong PTSD research does not equal routine legal access. As of this page update, MDMA-assisted therapy is not FDA-approved. People should verify current FDA status, trial availability, and legal access before making any plan.
Cost also differs. Ketamine may involve a series of clinic visits and possible maintenance. Psilocybin programs often bundle preparation, a long session, and integration. MDMA therapy protocols, where legal in research settings, are psychotherapy-intensive and not comparable to a single medication visit.
All three require screening. Psilocybin is typically avoided in people with personal or strong family history of psychosis or bipolar I disorder, and it has major medication concerns such as lithium and MAOIs. MDMA raises cardiovascular and overheating concerns and is not appropriate for every trauma patient. Ketamine can raise blood pressure, cause dissociation, and carries misuse and bladder-risk concerns with repeated nonmedical use.
Medication review is not optional. If you take psychiatric medications, blood pressure medications, stimulants, opioids, sedatives, or lithium, start with the drug interactions guide and talk to a licensed clinician before changing anything.
The focused two-way depression comparison: evidence, cost, session structure, and legal access.
Compare the two main U.S. supervised psilocybin access models by rules, cost, facilitator requirements, and travel fit.
Current evidence, veteran context, trauma mechanisms, and where psilocybin research is still early.
PTSD, moral injury, legal access, and how psilocybin compares with better-studied trauma therapies.
Medication screening before any psychedelic-assisted treatment, including lithium, MAOIs, SSRIs, and stimulants.